<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841110</url>
  </required_header>
  <id_info>
    <org_study_id>FT500-101</org_study_id>
    <nct_id>NCT03841110</nct_id>
  </id_info>
  <brief_title>FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive&#xD;
      immunity, and has the potential to overcome multiple mechanisms of immune checkpoint&#xD;
      inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the&#xD;
      clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.</measure>
    <time_frame>Day 29</time_frame>
    <description>The incidence of subjects with DLTs within each assessed dose level cohort to determine the MTD or MAD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective-response rate (ORR)</measure>
    <time_frame>Day 29 and every 8 weeks thereafter through Day 366</time_frame>
    <description>defined as the proportion of subjects who achieve iPR/PR or iCR/CR. Tumor response will be assessed using iRECIST or RECIL, as applicable.&#xD;
Protocol FT500-101 FT500 Monotherapy and in Combination with Immune Checkpoint Inhibitors Page 16 of 121 Protocol Version 5.0 Fate Therapeutics, Inc.âŽ¯Confidential and Proprietary The &quot;i&quot; prefix will be used throughout this protocol to denote iRECIST responses of iCR, iPR, iSD, iUPD, and iCPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of FT500 persistence</measure>
    <time_frame>Day 1 through Day 366</time_frame>
    <description>defined as duration from Day 1 to undetectable levels of FT500 cells per uL blood.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>EGFR Positive Solid Tumor</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Melanoma</condition>
  <condition>NSCLC</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Cervical Cancer</condition>
  <condition>Microsatellite Instability</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>FT500 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT500 administered once weekly for 3 weeks as a monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT500</intervention_name>
    <description>FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_label>FT500 Monotherapy</arm_group_label>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Immune Checkpoint Inhibitor</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Immune Checkpoint Inhibitor</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Immune Checkpoint Inhibitor</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <other_name>TECENTRIQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_label>FT500 Monotherapy</arm_group_label>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <arm_group_label>FT500 Monotherapy</arm_group_label>
    <arm_group_label>FT500 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Biologic response modifier</description>
    <arm_group_label>FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor</arm_group_label>
    <other_name>Proleukin</other_name>
    <other_name>Aldesleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Diagnosis of the following, as per Regimen Cohort:&#xD;
&#xD;
        1A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy,&#xD;
        including lymphoma, in a subject who has failed or refused available FDA-approved therapies&#xD;
        and is now a candidate for salvage therapy.&#xD;
&#xD;
        1B. Regimen B and BB (Dose Escalation): FT500 (+ IL-2, Regimen BB only) + ICI: An advanced&#xD;
        solid tumor malignancy, including lymphomas, that has progressed on treatment with at least&#xD;
        one ICI (ie, nivolumab, pembrolizumab or atezolizumab), in a subject who has also failed or&#xD;
        refused other available approved therapies and is now a candidate for salvage therapy.&#xD;
&#xD;
        1C. Regimen B(Dose Expansion): FT500 (+ IL-2, Regimen BB only) + ICI An advanced solid&#xD;
        tumor malignancy or lymphoma in a subject with disease relapse or progression on an ICI&#xD;
        (nivolumab, pembrolizumab, or atezolizumab) in an approved indication per the respective&#xD;
        USPI.&#xD;
&#xD;
        2. Willingness to provide informed consent as described in the protocol, which includes&#xD;
        compliance with the requirements and restrictions listed in the ICF and in this protoco 3.&#xD;
        Age &gt;18 years old at the time of signing the ICF 4. Presence of measurable disease by&#xD;
        iRECIST or RECIL criteria, assessed before the start of lympho-conditioning and within 28&#xD;
        days prior to Day 1 5. Contraceptive use by women or men should be consistent with local&#xD;
        regulations regarding the methods of contraception for those participating in clinical&#xD;
        studies&#xD;
&#xD;
          1. Female subjects: Women of childbearing potential (WOCBP) must use a highly effective&#xD;
             form of contraception from the screening visit until at least 12 months after the&#xD;
             final dose of CY, at least 4 months after the final dose of FT500, at least 4 months&#xD;
             after the final dose of pembrolizumab, and at least 5 months after the final dose of&#xD;
             nivolumab or atezolizumab, whichever is latest.&#xD;
&#xD;
          2. Male subjects: Males must be sterile (biologically or surgically) or use a highly&#xD;
             effective method of contraception from the screening visit until at least 14 months&#xD;
             after the final dose of CY, at least 6 months after the final dose of FT500, at least&#xD;
             6 months after the final dose of pembrolizumab, and at least 7 months after the final&#xD;
             dose of nivolumab or atezolizumab, whichever is latest 6. Willingness to comply with&#xD;
             study procedures through the planned study duration. For patients with &gt;1 measurable&#xD;
             lesion, agreement to undergo a biopsy from a safely accessible site per Investigator&#xD;
             assessment for exploratory biomarker assessments.&#xD;
&#xD;
             7. Provision of signed and dated ICF to agree to participate, at time of withdrawal or&#xD;
             completion of this study, in Fate Therapeutics' long-term, non-interventional,&#xD;
             observational study, FT-003&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Subjects:&#xD;
&#xD;
          1. Females who are pregnant or breastfeeding&#xD;
&#xD;
          2. ECOG performance status â‰¥ 2.&#xD;
&#xD;
          3. Evidence of insufficient organ function as determined by any one of the following:&#xD;
&#xD;
               1. Neutrophils &lt;1000/ÂµL or platelets &lt;75,000/ÂµL.&#xD;
&#xD;
               2. Estimated creatinine clearance &lt;50 mL/minute (Cockcroft-gault).&#xD;
&#xD;
               3. Total bilirubin &gt;2 x upper limit normal (ULN) with the exception of subjects with&#xD;
                  Gilbert's Syndrome or known liver metastases.&#xD;
&#xD;
               4. Aspartate aminotransferase (AST) &gt;3 x ULN, or alanine aminotransferase (ALT) &gt;3 x&#xD;
                  ULN. For subjects with known liver metastases, AST or ALT &gt;5 x ULN.&#xD;
&#xD;
               5. Oxygen saturation &lt;90% on room air&#xD;
&#xD;
               6. Left ventricular ejection fraction (LVEF) &lt;40% (eg by echocardiogram (ECHO) or ]&#xD;
                  multi-gated acquisition (MUGA) scan).&#xD;
&#xD;
          4. Receipt of any biological therapy, chemotherapy, or radiation (except palliative&#xD;
             radiation) within 2 weeks prior to Day 1. Subjects in Regimen B currently taking an&#xD;
             ICI must interrupt ICI dosing at least 2 weeks prior to Day 1.&#xD;
&#xD;
          5. CNS metastases that have not been treated; or treated CNS metastases that have not&#xD;
             been stable for at least 4 weeks.&#xD;
&#xD;
          6. Clinically significant cardiovascular disease, including stroke or myocardial&#xD;
             infarction within 6 months prior to first study medication; or the presence of&#xD;
             unstable angina or congestive heart failure of New York Heart Association grade 2 or&#xD;
             higher.&#xD;
&#xD;
          7. Currently receiving or likely to require systemic immunosuppressive therapy (eg,&#xD;
             prednisone &gt;5 mg daily) for any reason from Day -7 to Day 29.&#xD;
&#xD;
          8. Uncontrolled infections.&#xD;
&#xD;
          9. Known allergy to the following FT500 components: Albumin (Human) or DMSO.&#xD;
&#xD;
         10. Presence of any medical or social issues that are likely to interfere with study&#xD;
             conduct, or may cause increased risk to subject.&#xD;
&#xD;
         11. Any medical condition or clinical laboratory abnormality that, per Investigator or&#xD;
             Medical Monitor judgement, precludes safe participation in and completion of the&#xD;
             study, or that could affect compliance with protocol conduct or interpretation of&#xD;
             results Subjects who have had prior receipt of a Fate Therapeutics investigational&#xD;
             human iPSC product may be eligible for the study with approval from the Medical&#xD;
             Monitor.&#xD;
&#xD;
        Additional Exclusion Criteria for Regimen B: FT500 + ICI:&#xD;
&#xD;
        11. Subjects who experienced an ICI-related adverse reaction that resulted in&#xD;
        discontinuation of the ICI.&#xD;
&#xD;
        12. Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid&#xD;
        arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's disease,&#xD;
        ulcerative colitis), except for subjects with isolated vitiligo, atopic dermatitis,&#xD;
        controlled hypoadrenalism or hypopituitarism, and controlled thyroid disease.&#xD;
&#xD;
        13. Subjects who have received an allograft organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Chou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Musni</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Albers</last_name>
    <phone>858-875-1800</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center/John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>NK cell therapy</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Checkpoint Inhibitor</keyword>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Cellular therapy</keyword>
  <keyword>nivolumab</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>atezolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

